Back to Results
First PageMeta Content



PIPELINE WATCH Latanoprost SPC ends in top EU markets n mid-January, Pfizer’s blockbuster treatment for glaucoma and ocular hypertension, Xalatan (latanoprost), loses supplementary protection certificate (SPC) exclusi
Add to Reading List

Document Date: 2012-01-23 01:55:50


Open Document

File Size: 37,90 KB

Share Result on Facebook